U.S. Stem Cell, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From U.S. Stem Cell, Inc.
Teleflex markets the UroLift minimally invasive system for managing symptomatic benign prostate hyperplasia. Palette sells five urology products, including Barrigel spacer gel for prostate radiotherapy.
Operating on slim margins towards the launch of its Enos single port surgical robot, Titan Medical needs to refocus its efforts to succeed, according to its new CEO Cary Vance.
Medtech Insight interviewed the CEO of Ceros Financial Services and its investment banking division, Ceros Capital Markets, about the firm’s considerations for funding early-stage medtechs, and outlook for medtech fundraising, in this uncertain economic climate.
Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the Top 50 global medtechs share their perspectives on the present and the future, from company and health care system standpoints.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Bioheart Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.